A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Open Access
- 14 November 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (22), 7127-7138
- https://doi.org/10.1158/1078-0432.ccr-11-1157
Abstract
Purpose: The c-MET receptor tyrosine kinase plays important roles in the formation, progression, and dissemination of human cancer and presents an attractive therapeutic target. This study describes the preclinical characterization of INCB28060, a novel inhibitor of c-MET kinase. Experimental Design: Studies were conducted using a series of in vitro and in vivo biochemical and biological experiments. Results: INCB28060 exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10,000-fold selectivity over a large panel of human kinases. This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET–dependent tumor cell lines. As a result, INCB28060 potently inhibits c-MET–dependent tumor cell proliferation and migration and effectively induces apoptosis in vitro. Oral dosing of INCB28060 results in time- and dose-dependent inhibition of c-MET phosphorylation and tumor growth in c-MET–driven mouse tumor models, and the inhibitor is well tolerated at doses that achieve complete tumor inhibition. In a further exploration of potential interactions between c-MET and other signaling pathways, we found that activated c-MET positively regulates the activity of epidermal growth factor receptors (EGFR) and HER-3, as well as expression of their ligands. These effects are reversed with INCB28060 treatment. Finally, we confirmed that circulating hepatocyte growth factor levels are significantly elevated in patients with various cancers. Conclusions: Activated c-MET has pleiotropic effects on multiple cancer-promoting signaling pathways and may play a critical role in driving tumor cell growth and survival. INCB28060 is a potent and selective c-MET kinase inhibitor that may have therapeutic potential in cancer treatment. Clin Cancer Res; 17(22); 7127–38. ©2011 AACR.Keywords
Other Versions
This publication has 33 references indexed in Scilit:
- Phosphorylation State-Dependent High Throughput Screening of the c-Met KinaseCurrent Chemical Genomics, 2010
- Developing c-MET pathway inhibitors for cancer therapy: progress and challengesTrends in Molecular Medicine, 2010
- Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid TumorsClinical Cancer Research, 2010
- Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancerProceedings of the National Academy of Sciences of the United States of America, 2009
- HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell CancerClinical Cancer Research, 2009
- Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer PatientsJournal of Clinical Oncology, 2009
- The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell CarcinomaCancer Research, 2009
- Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate CancerClinical Cancer Research, 2008
- Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancerCancer Science, 2008
- Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth FactorMolecular Cancer Research, 2008